Although IL-6 blockade by tocilizumab or sarilumab is a rational way to decrease cytokine-driven TPO induction, it carries class-specific risks such as increased incidence of bacterial infections, blunts fever and CRP, potentially masking infection and elevated liver enzymes, neutropenia, thrombocytopenia, and lipid increases are also described [79]. Here, IL6 is linked to infection.